U.S. Physical Therapy (USPH) Raised to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of U.S. Physical Therapy (NYSE:USPH) from a hold rating to a buy rating in a report released on Saturday morning. Zacks Investment Research currently has $82.00 target price on the stock.
According to Zacks, “U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics, with over 500 Clinics in 42 States. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh’s clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company’s growth, are structured like the de novo partnerships, with significant ownership retained by founders. “
USPH has been the subject of a number of other reports. Barrington Research downgraded shares of U.S. Physical Therapy from an outperform rating to a market perform rating in a research report on Friday, November 3rd. BidaskClub raised shares of U.S. Physical Therapy from a strong sell rating to a sell rating in a research report on Thursday, September 28th. Cantor Fitzgerald reissued a buy rating and set a $74.00 target price on shares of U.S. Physical Therapy in a research report on Thursday, November 2nd. Finally, Sidoti raised shares of U.S. Physical Therapy from a neutral rating to a buy rating and increased their target price for the company from $62.00 to $74.00 in a research report on Friday, September 8th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $73.80.
U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.52 by ($0.04). The firm had revenue of $103.03 million during the quarter, compared to analysts’ expectations of $102.69 million. U.S. Physical Therapy had a net margin of 5.29% and a return on equity of 13.37%. equities research analysts forecast that U.S. Physical Therapy will post 2.07 earnings per share for the current year.
In related news, CFO Lawrance W. Mcafee sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $72.56, for a total value of $145,120.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher J. Reading sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $66.52, for a total transaction of $997,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 31,875 shares of company stock valued at $2,173,623 over the last three months. Insiders own 3.10% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in USPH. Pinebridge Investments L.P. lifted its stake in U.S. Physical Therapy by 1.0% in the 2nd quarter. Pinebridge Investments L.P. now owns 1,650 shares of the company’s stock worth $100,000 after purchasing an additional 17 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in U.S. Physical Therapy by 3.0% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 6,868 shares of the company’s stock worth $415,000 after purchasing an additional 200 shares in the last quarter. Thrivent Financial For Lutherans lifted its stake in U.S. Physical Therapy by 5.9% in the 2nd quarter. Thrivent Financial For Lutherans now owns 7,570 shares of the company’s stock worth $457,000 after purchasing an additional 420 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in U.S. Physical Therapy by 1.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 53,637 shares of the company’s stock worth $3,240,000 after purchasing an additional 541 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in U.S. Physical Therapy by 31.8% in the 2nd quarter. Sei Investments Co. now owns 2,576 shares of the company’s stock worth $155,000 after purchasing an additional 622 shares in the last quarter. 94.12% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/u-s-physical-therapy-usph-raised-to-buy-at-zacks-investment-research/1800602.html.
U.S. Physical Therapy Company Profile
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.